Cancers, Volume 14, Issue 23
2022 December-1 - 296 articles
Cover Story: A large arsenal of therapeutic options (surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy) has been approved for the treatment of non-small-cell lung cancer (NSCLC). However, patients with advanced NSCLC have an abysmal prognosis due to a propensity to acquire resistance to therapies. In recent decades, much effort has been made to explore the molecular mechanisms at the basis of drug resistance, where microRNAs (small non-coding RNA that regulate gene expression) were found to play key roles. Here, we provide an update of the current knowledge of the role of miRNAs in driving resistance to drugs currently used in the clinic. We also critically discuss how the current experimental approaches can be improved to foster the translation to clinical practice of new discoveries in this field. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.